RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
Status:
Completed
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early
Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.